The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy. [Status: RECRUITING | Phase: PHASE3 | Sponsor: DBV Technologies]
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
|ClinicalTrials.gov